Amgen Stock News

Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd. Major players in the adalimumab, infliximab and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd.

Amgen Inc. ( AMGN , Financial) is a well-known pharma and biotech player. The company has been delivering a string of decent financial results, and the most recent quarter was no exception, with Amgen

THOUSAND OAKS, Calif. , March 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the second quarter of 2022. The dividend will be paid on June 8, 2022 , to all stockholders of record as of the close of business on May 17,

President Joe Biden hosted his first State of the Union Address Tuesday in front of members of Congress. In the speech, Biden discussed several items that he has already helped pass along with more future initiatives. Here is a look at stocks to watch after the State of the Union address. Pharmaceutical Companies : In 2016, then- Vice President Biden launched the Cancer Moonshot program the help boost spending on medical research to take on various types of cancer. In 2022, Biden announced plans to boost spending and reduce the death rate from cancer by 50% over the next 25 years. The Partnership for Accelerating Cancer Therapies includes 11 companies working to boost treatments for various types of cancers. The companies are AbbVie Inc (NYSE: ABBV ), Amgen Inc (NASDAQ: AMGN ), Boehringer-Ingelheim Pharma , Bristol-Myers Squibb Co (NYSE: BMY ), Celgene (owned by Bristol-Myers Squibb), Genetech (owned by Roche ), Gilead Sciences (NASDAQ: GILD ), GlaxoSmithKline (NYSE: GSK ), Janssen Research (owned by Johnson & Johnson (NYSE: JNJ )), Novartis (NYSE: NVS ), Sanofi SA (NASDAQ: SNY ) and Pfizer Inc (NYSE: PFE ).

THOUSAND OAKS, Calif., March 2, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will virtually present at the 42nd Annual Cowen Healthcare Conference at 11:10 a.m.

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration."

Amgen Inc (NASDAQ: AMGN ) shared results from a pooled post-hoc analysis of the NAVIGATOR Phase 3 and PATHWAY Phase 2b trials of Tezspire (tezepelumab-ekko) in broad asthma patient population. Tezspire is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. In the pooled … Full story available on Benzinga.com

10 Dividend Growth Stocks For February 2022

Week 9 MDA Breakout Stocks - March 2022: Short-Term Picks To Give You An Edge

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com''s offering. The global regenerative medicine market reached a value of US$ 14.78 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 50.44 Billion by 2027, exhibiting a CAGR of 22.6% during 2022-2027. Companies Mentioned Allergan PLC (AbbVie Inc.) Amgen Inc. Baxter International In

Summary We are CORRECTING our initiating coverage of Can-Fite BioPharma Ltd. (“Can Fite” or the “company”), a clinical-stage pharmaceutical company, with an OUTPERFORM rating and $6.00 price target (CORRECTION from the previous, initiated $2 price target). With a pipeline of proprietary small molecule drugs treating inflammation, cancer and liver diseases, we believe Can-Fite is poised to register material progress in commercializing its compounds in 2022, including the imminent release of Phase III trial data for the treatment of psoriasis. Further, with a business model predicated on licensing compounds to leading international pharmaceutical players, we believe new contracts and territory expansion will refocus investors on Can-Fite’s myriad positives. As such, we view the risk/reward in CANF as impressive and are initiating coverage with an OUTPERFORM rating and a $6.00 price target. Key Points Focused on A3 adenosine receptor (“A3AR”) . A3AR has a high incidence in cancer and inflammatory cells, which allows the company’s compounds to target A3AR and destroy the corresponding cells.

If history is any guide, there may be good fortune ahead for shares of Amgen (NASDAQ: AMGN ). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. What To Know: Many traders use moving average crossover systems to make their decisions. When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses below the long-term Full story available on Benzinga.com

Biotechnology company Amgen announced today the issuance of its inaugural $750 million green bond, with proceeds aimed at financing environmental impact mitigation projects in areas including renewable energy and green transportation. The bond has a 3.000% semi-annual coupon and matures in 2029. The issuance follows the launch last year by Amgen of a seven-year environmental [] The post Amgen Launches $750 Million Green Bond to Fund Environmental Impact Mitigation Projects appeared first on ESG Today .

The Osteoporosis Treatment Market reports aims to convey a reasonable understanding of the business which has been analyzed by using primary and secondary research strategies. The major purpose of this Osteoporosis Treatment Market report is to provide an in-depth view

Amgen (AMGN) issued its inaugural $750M green bond, with a 3% semi-annual coupon and maturing in 2029, to advance the environmental goals that are part of AMGN''s ESG framework.The